Qiagen Agrees to EQT Takeover at €46.50 a Share, a €10.8 Billion Enterprise Value

Qiagen moved to end years of takeover speculation on Wednesday, Oct. 21, entering a business combination agreement under which Crown NL Bidco, a bidder controlled by EQT's EQT XI fund with co-investors from Abu Dhabi and Canada, will make a voluntary public tender offer of €46.50 in cash for every Qiagen share. Both of Qiagen's boards approved the agreement unanimously and agreed to recommend the offer, giving the long-running question over the diagnostics company's ownership a price, a structure and a timetable at last.

The agreement, announced from Venlo in an ad hoc release late Wednesday, covers all issued ordinary shares of Qiagen. The bidder is indirectly controlled by the EQT XI fund, with further indirect stakes held by Luxinva, a wholly owned subsidiary of the Abu Dhabi Investment Authority, and by a wholly owned subsidiary of Canada Pension Plan Investment Board. Qiagen said the deal followed a comprehensive review that assessed its strategic prospects and included discussions with both strategic and financial parties — language that tells shareholders the board shopped the company before settling on this buyer at this price.

Two valuations, one offer price — and why they differ

Qiagen valued the transaction at approximately €10.8 billion in enterprise value, about $12.1 billion including approximately $1.1 billion of net debt. That is not the same number as the roughly €9.6 billion, or $10.78 billion, equity value in the headline of the Reuters report on the deal: enterprise value counts the debt a buyer assumes on top of what shareholders are paid, while equity value is the offer price multiplied across the shares. Readers who see both figures are looking at one transaction measured two ways, not at two competing bids. On the price itself there is no ambiguity: €46.50 in cash per share, which Reuters noted works out to $52.22 a share and an 8.6% premium to the last close. The larger premiums Qiagen cites are measured against older reference points — a 40.3% premium to the unaffected price as of July 8, 2026, the last trading day before market reports of private-equity takeover interest, when the shares closed at €33.15, and a 46.9% premium to the three-month volume-weighted average price of €31.66 over the same period. The gap between the 8.6% and the 40.3% is itself information: the market had already priced in much of a deal before one was signed.

What shareholders are being asked to accept

A tender offer is not a merger vote: the bidder is asking each shareholder individually to sell at €46.50, and the offer stands or falls first on how many accept. The minimum acceptance threshold is 50% of the outstanding share capital plus one share. Alongside the tender, shareholders will be asked at an extraordinary general meeting held during the initial acceptance period to approve post-closing measures designed to give the bidder full ownership of the entire business. Holders who do not tender would then receive a cash distribution per share equal to the offer price less applicable withholding taxes, which Qiagen noted may leave them with less than tendering would have paid. Once those measures are implemented, the listings in Frankfurt and New York will be terminated. The boards will take the decision to implement the measures if they are approved at the meeting by at least 80% of the votes cast, and they have reserved a fiduciary path to proceed on a lower vote if they judge a substantial majority of the shareholder base supports the deal.

The case the boards made for going private

"This transaction offers shareholders compelling value while positioning QIAGEN for its next phase of development under private ownership," Stephen H. Rusckowski, chairman of the supervisory board, said in the joint announcement, adding that after considering the stand-alone prospects and the alternatives raised in discussions with strategic and financial parties, the boards "unanimously concluded that this is the best path forward." Chief Executive Jonathan M. Pratt argued that under private ownership Qiagen "can move faster and have greater freedom to put resources behind the most attractive opportunities." For the buyer, EQT partner Matteo Thun-Hohenstein called Qiagen "an outstanding global leader in the life science tools and diagnostics market" that EQT has followed for many years. The financing, at least, is not a condition left hanging: the joint announcement said EQT has obtained committed equity and debt financing sufficient to fund the offer and its costs, and that the transaction is not subject to any financing condition. Qiagen will keep its name and brand, and EQT committed in the agreement to support its strategy, key brands, operational footprint, research and development, and employee arrangements.

A preliminary quarter tucked inside the deal announcement

The same ad hoc release carried Qiagen's preliminary third-quarter 2026 results: net sales of $548 million, at both reported exchange rates and constant exchange rates, and adjusted diluted earnings per share of $0.65, also $0.65 at constant rates. Those figures are preliminary and unaudited in the form released, and they arrived without the fuller segment detail of a scheduled earnings report. Qiagen also suspended its full-year 2026 outlook while the transaction is pending — a common step once a board has agreed to sell the company, since guidance written for a stand-alone business no longer describes the business being bought, but one that leaves investors valuing the shares against the offer price rather than against a forecast. Until closing, Qiagen said, it will continue to operate as an independent company under its current management.

What stands between here and a mid-2027 close

Closing is currently expected in mid-2027, a long runway explained by the conditions still outstanding: merger-control and foreign-investment clearances, the meeting vote and implementation decision described above, and the offer document itself, which must first clear the German financial regulator before the acceptance period can begin and the boards publish their formal reasoned recommendation. One provision prices the wait. If closing has not occurred within ten months of the announcement because regulatory approvals are still pending, Qiagen may elect to pay shareholders an interim dividend of up to $0.47 per share — and any such dividend would not be deducted from the offer price. What to watch, in order: publication of the offer document and the acceptance timetable, the meeting's vote on the post-closing measures against that 80% marker, and the pace of the regulatory clearances that decide whether the interim-dividend clause is ever triggered. Reuters framed the signing as the end of years of takeover speculation around the European diagnostics firm, amid growing private-equity appetite for molecular-testing assets. The speculation is over. The execution risk — a year of approvals for a fixed cash price — is what shareholders now own.